(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 26.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Aurinia Pharmaceuticals's revenue in 2024 is $191,407,000.On average, 4 Wall Street analysts forecast AUPH's revenue for 2024 to be $32,999,859,222, with the lowest AUPH revenue forecast at $31,492,864,173, and the highest AUPH revenue forecast at $33,881,287,569. On average, 4 Wall Street analysts forecast AUPH's revenue for 2025 to be $41,742,633,004, with the lowest AUPH revenue forecast at $38,672,436,296, and the highest AUPH revenue forecast at $45,545,946,978.
In 2026, AUPH is forecast to generate $57,501,650,795 in revenue, with the lowest revenue forecast at $56,451,173,559 and the highest revenue forecast at $58,552,128,031.